Quick Answer
Transcode Therapeutics, Inc. reported R&D Expense of $9.71 million for fiscal year 2024.
Transcode Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $9.71M | -20.9% |
| 2023 | $12.26M | +19.9% |
| 2022 | $10.23M | +271.6% |
| 2021 | $2.75M | +868.1% |
| 2020 | $284.5K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.16M | +157.5% | +23.2% |
| June 30, 2025 | $2.57M | -16.7% | +15.6% |
| March 31, 2025 | $2.22M | +26.2% | +80.8% |
| September 30, 2024 | $1.23M | -63.3% | -60.2% |
| June 30, 2024 | $3.08M | +3.9% | +75.2% |
| March 31, 2024 | $1.76M | -32.1% | -47.4% |
| September 30, 2023 | $3.34M | +9.8% | +12.7% |
| June 30, 2023 | $2.97M | +13.2% | +14.5% |
- Transcode Therapeutics, Inc. showed a decrease of -20.9% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2024 period, Transcode Therapeutics, Inc.’s r&d expense has grown by 3312.2% (from $284.5 thousand to $9.71 million).
- The most recent figure is from Transcode Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: